NCT05758480Completed
Characterization of the Immunometabolic Signature in Long COVID-19.
Source: ClinicalTrials.gov · Last updated 20 Jul 2026
Brief summary (registry, in English)
The primary objective of this study is to identify immunometabolic signatures associated with Long COVID in plasma and peripheral blood mononuclear cells (PBMC).
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 62 (actual)
- First submitted
- 1 Mar 2023
- Start date
- 24 May 2023
- Primary completion date
- 7 May 2025
- Lead sponsor
- University Hospital, Angers
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT05758480
What you commit to
- Study type: Interventional
- Participants enrolled: 62
- From 24 May 2023 to the primary completion date, 7 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- A/ Inclusion Criteria:
- For all patients:
- Age \> 18 years
- Symptomatic COVID-19 diagnosed after 01JAN2021, confirmed by RT-PCR or Antigen test
- Last SARS-CoV-2 infection diagnosed more than 12 weeks before inclusion
- Patient covered by the French health insurance
- Signature of the informed consent
- For patient with Long COVID :
- At least one of the following symptoms during the week preceding inclusion: abnormal fatigue, dyspnoea sine materia, abnormal pain (chest, joint, muscle, headache), unusual neurocognitive disorders (concentration disorders, "brain fog", language/memory disorders, paraesthesia)
- Absence of Return to Usual Health after SARS-CoV-2 infection (patient declaration)
- Absence of alternative diagnosis for the symptoms
- For COVID-19 recovered patient (Control) :
- None of the following symptoms in the 3 week before inclusion: abnormal fatigue, dyspnoea sine materia, abnormal pain (chest, joint, muscle, headache), unusual neurocognitive disorders (concentration disorders, "brain fog", language/memory disorders, paraesthesia)
- Return to Usual Health after SARS-CoV-2 infection (patient declaration)
- B/ Exclusion Criteria:
- History of severe COVID-19 (Hospitalization)
- Symptoms caused by sequelae of SARS-CoV-2 infection (in particular, persistence of lung parenchymal abnormalities : pulmonary fibrosis, persistent alveolitis on CT-Scan)
- Significant Depression or anxiety symptoms, as assessed by a \> 10 score on the A or D items of the Hospital anxiety and depression scale (HAD)
- Presence of one of the following diseases:
- Inborn errors of metabolism
- estimated Glomerular filtration rate \< 30 ml/min (MDRD)
- Autoimmune disease
- Immunosuppressive treatment or immune deficiency
- Symptomatic heart failure
- Respiratory failure (COPD stage ≥ 3 or oxygen therapy)
- Solid cancer or active blood disease
- Severe malnutrition (albumin \< 30 g/L or weight loss ≥10% in 6 months)
- Obesity with BMI ≥ 35 kg/m²
- Diabetes not controlled by diet alone
- Pregnant, breastfeeding or parturient women
- Deprivation of liberty by judicial or administrative decision
- Mandatory Psychiatric Care
- Protected by decision of law
- Unable to express consent
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Angers University Hospital Coordinator of this site? Confirm its status | Angers | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.